A Pivotal phase II Clinical Trial to Evaluate MB-207 in Previously Transplanted Patients with X-Linked Severe Combined Immunodeficiency (XSCID)
Latest Information Update: 19 Aug 2022
Price :
$35 *
At a glance
- Drugs MB 107 (Primary)
- Indications Immunodeficiency disorders; X-linked genetic disorders
- Focus Registrational; Therapeutic Use
- Sponsors Mustang Bio
- 11 Aug 2022 According to a Mustang Bio media release, the company expects to enroll the first patient in trial in 2023.
- 27 Jul 2022 According to a Mustang Bio media release, this trial is expected to begin in the second half of 2022.
- 23 Mar 2022 According to a Mustang Bio media release, in the second half of 2022 the company expects to enroll the first patient in Mustangs multicenter pivotal Phase 2 clinical trial to evaluate MB-107.